A Croatian technology transfer company is offering a new antiviral zeolite-based preparation for prophylaxis, therapy and pre- or post- treatment of diseases caused by the infection with Herpes Simplex virus type 1 and 2. When applied in low concentrations, they retard entry of viruses into the cell and at the same time inhibit their propagation (up to 92 %). Since invention is only in vitro tested, further development and funding partner is needed.